Premium
Proteasome inhibition and Parkinson's disease modeling
Author(s) -
Bové Jordi,
Zhou Chun,
JacksonLewis Vernice,
Taylor Julie,
Chu Yaping,
Rideout Hardy J.,
Wu DuChu,
Kordower Jeffrey H.,
Petrucelli Leonard,
Przedborski Serge
Publication year - 2006
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20937
Subject(s) - proteasome , dopaminergic , parkinson's disease , neuroscience , abnormality , disease , degeneration (medical) , mechanism (biology) , proteasome inhibitor , dopamine , medicine , psychology , biology , pathology , microbiology and biotechnology , psychiatry , philosophy , epistemology
Impaired proteasome function is a potential mechanism for dopaminergic neuron degeneration. To model this molecular defect, we administered systemically the reversible lipophilic proteasome inhibitor, carbobenzoxy‐ L ‐isoleucyl‐γ‐t‐butyl‐ L ‐glutamyl‐ L ‐alanyl‐ L ‐leucinal (PSI), to rodents. In contrast to a previous report, this approach failed to cause any detectable behavioral or neuropathological abnormality in either rats or mice. Although theoretically appealing, this specific model of Parkinson's disease appears to exhibit poor reproducibility. Ann Neurol 2006;60:260–264